Pharmacoeconomic analysis of therapy of acute exacerbation of chronic obstructive pulmonary disease in a large Krasnoyarsk hospital
https://doi.org/10.18093/0869-0189-2015-25-3-320-326
Abstract
The aim of this study was to evaluate cost structure and rationality of pharmacotherapy of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a pulmonology department of a multiprofile Krasnoyarsk hospital in 2014. Methods. This was a retrospective 1-year study evaluating pharmacotherapy of AECOPD according to electronic medical reports. Medication therapy and frequency of administration of certain drugs were evaluated using frequency analysis. Rationality of medication therapy and treatment expenses were analyzed with ABC/VEN analysis. Results. One hundred and thirty one electronic medical reports were analyzed. Frequency analysis showed that all patients received the combined bronchodilator Berodual and the expectorant bromhexine. Moreover, 81.7% of patients received antibiotics, 75.6% received systemic steroids and 41.2% received inhaled corticosteroids. This is consistent with current scientific trends and recent recommendations. ABC/VEN-analysis showed a rational pharmacotherapy expenditure of funds in patients with AECOPD. The main expenses were associated with vital drugs (58.2%) followed by pharmacotherapy of comorbidity (41.8%) which was administered to 87.8% of the patients. Anticoagulants had the highest cost (22.5% of the total pharmacotherapy of AECOPD). Second-line drugs were not used in the treatment of AECOPD. Conclusion. The main portion of cost of AECOPD pharmacotherapy was related to pathogenic treatment followed by treatment for comorbidity and prevention as the former greatly effects severity and outcomes of COPD.
About the Authors
T. V. Gaygol'nik
State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia: 1, Partizana Zheleznyaka str., Krasnoyarsk, 660022, Russia
Russian Federation
Russian Federation
PhD student, Department of Internal Medicine N2, State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia; tel.: (902) 913-15-39;
I. V. Demko
State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia: 1, Partizana Zheleznyaka str., Krasnoyarsk, 660022, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Department of Internal Medicine N2, State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia; tel.: (913) 507-84-08;
E. N. Bochanova
State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia: 1, Partizana Zheleznyaka str., Krasnoyarsk, 660022, Russia
Russian Federation
Russian Federation
PhD, Associate Professor, Department of Pharmacology, State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia; tel.: (913) 522-16-58;
N. V. Gordeeva
State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia: 1, Partizana Zheleznyaka str., Krasnoyarsk, 660022, Russia
Russian Federation
Russian Federation
Gordeeva Natal'ya Vladimirovna, PhD, Senior Researcher, Department of Internal Medicine N2, State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia; tel.: (913) 199-06-53;
A. Yu. Kraposhina
State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia: 1, Partizana Zheleznyaka str., Krasnoyarsk, 660022, Russia
Russian Federation
Russian Federation
PhD, Assistant Lecturer, Department of Internal Medicine N2, State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia; tel.: (902) 990-37-67;
I. A. Solov'eva
State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia: 1, Partizana Zheleznyaka str., Krasnoyarsk, 660022, Russia
Russian Federation
Russian Federation
PhD, Assistant Lecturer, Department of Internal Medicine N2, State Institution «V.F.Voyno-Yasenetskiy Krasnoyarsk State Medical University», Healthcare Ministry of Russia; tel.: (913) 835-26-43;
References
1. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9 (1): 963–974.
2. Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: методические рекомендации. Пульмонология. 2014; 3: 15–36.
3. Крысанов И.С. Анализ стоимости хронической обструктивной болезни легких в Российской Федерации. Качественная клиническая практика. 2014; 2: 51–56.
4. Gibson G.J., Loddenkemper R., Sibille Y., Lundback B. The European Lung White Book. Sheffield: European Respiratory Society; 2013 Available from: http://www.erswhitebook.org/files/public/Chapters/13_COPD.pdf (Accessed Feb. 14, 2015).
5. The American Lung Association. Epidemiology and statistics unit. Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and mortality 2013. Available from: http://www.lung.org/finding-cures/our-research/trend-reports/copd-trend-report.pdf (Accessed Feb. 11, 2015).
6. Perera P.N., Armstrong E.P., Sherrill D.L. et al. Acute exacerbations of COPD in the United States: Inpatient burden and predictors of costs and mortality. Int. J. Chron. Obstruct. Pulm. Dis. 2012; 9 (2): 131–141.
7. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease; 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (Accessed Feb. 4, 2015).
8. Чучалин А.Г., ред. Респираторная медицина. М.: ГЭОТАР-Медиа; 2007. Т. 1.
9. Mannino D.M., Higuchi K., Yu T.-C. et al. Economic burden of chronic obstructive pulmonary disease by presence of comorbidities. Chest. Published online Feb. 12, 2015. 10.1378/chest.14-2434. Available from: http://journal.publications.chestnet.org/article.aspx?articleID=2119206 (Accessed Feb. 23, 2015).
10. Fabbri L.M., Luppi F., Begh#é B et al. Complex chronic comorbidities of COPD Eur. Respir. J. 2008; 31: 204–212.
11. Воробьев П.А., ред. Клинико-экономический анализ М.: Ньюдиамед; 2008.
12. Савельев В.С., Гельфанд Б.Р., Яковлев С.В. Стратегия и тактика применения антимикробных средств в лечебных учреждениях России: Российские национальные рекомендации М.: ООО «Компания БОРГЕС»; 2012.
13. Stefan M.S., Rothberg M.B., Shieh M.S. et al. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest. 2013; 143 (1): 82–90.
14. Авдеев С.Н. Хроническая обструктивная болезнь легких: обострения. Пульмонология. 2013; 3: 5–19.
15. Яковлев С.В., Сидоренко С.В., Рафальский В.В., Спичак Т.В. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике: Российские практические рекомендации. М.: Престо; 2014.
16. Kahn S.R., Lim W., Dunn A.S. et al. Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2): 195–226.
17. Белоусов Д.Ю., Афанасьева Е.В., Кириенко А.И. и др. Фармакоэпидемиологическая и клинико-экономическая оценка профилактики венозных тромбоэмболических осложнений (реальная практика назначений). Качественная клиническая практика. 2013; 2: 2–17.
18. Степашкин К.Н., Петрова М.М., Демко И.В. Влияние коморбидной кардиоваскулярной патологии на качество жизни больных хронической обструктивной болезнью легких. Сибирское медицинское обозрение. 2013; 4: 66–69.
19. Коррейа Л.Л., Лебедев Т.Ю., Ефремова О.А. и др. Проблема полиморбидности при сочетании хронической обструктивной болезни легких и некоторых сердечно-сосудистых заболеваний. Научные ведомости БелГУ. Серия: Медицина. Фармация. 2013 (вып. 21); 4 (147): 12–17.
20. Au D.H., Bryson C.L., Fan V.S. et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patient with chronic obstructive pulmonary disease. Am. J. Med. 2004; 117 (12): 925–931.
Review
For citations:
Gaygol'nik T.V., Demko I.V., Bochanova E.N., Gordeeva N.V., Kraposhina A.Yu., Solov'eva I.A. Pharmacoeconomic analysis of therapy of acute exacerbation of chronic obstructive pulmonary disease in a large Krasnoyarsk hospital. PULMONOLOGIYA. 2015;25(3):320-326. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-3-320-326
Views:
870
Email this article 